Hologic to Showcase Game-Changing Breast Tomosynthesis Technology and Other Product Innovations at the European Congress of Radiology in Vienna

BEDFORD, Mass., Feb. 25, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will display an extensive suite of healthcare solutions for breast cancer screening and diagnosis, breast biopsy, osteoporosis risk assessment, medical MRI coils, and extremity imaging at the annual meeting of the European Society of Radiology, in Vienna, Austria March 7 – 11. The European Congress of Radiology (ECR), the largest radiological meeting in Europe, annually attracts over 20,000 participants representing the medical specialty of radiology throughout Europe and many other countries of the world.

"All eyes in the radiology community are on Vienna in March and the five-day European Congress of Radiology," said David Harding, Hologic's Senior Vice President and General Manager, International. "We believe this will be an exceptionally exciting time to reach out to the radiology world with our newest innovations in imaging. Of particular interest this year are advances in our breast tomosynthesis program, including the introduction of a tomosynthesis biopsy option for our Affirm breast biopsy guidance system. In addition, a significant number of peer-reviewed papers have been accepted by major scientific journals, including the recent publication of the results of the Oslo Breast Tomosynthesis Screening Trial. This and other publications continue to build support for the benefits of Hologic's breast tomosynthesis - improved accuracy compared to conventional mammography, resulting in earlier detection of cancers and a reduced need for recalls."   

Hologic Is Offering Three Special Tomosynthesis-related Events at ECR:

• A special ECR Satellite Symposium, "Celebrating the Evolution of Tomosynthesis," on Saturday, March 9 from 2:00 to 3:30 p.m. in the Austria Center Vienna, Room C.  The symposium will focus on:
     
  The Oslo Tomosynthesis Screening Trial Results - Per Skaane, Professor Dr. Med., Oslo University Hospital Ullevaal, Oslo, Norway
     
  Initial Experience with Tomosynthesis-guided Biopsy - Dr. Daniela Bernardi, Division U.O. Senologia Clinica e Screening Mammografico, Dipartimento di Radioliagnostica, Trento, Italy
      
  A Review of the Evolution of Breast Tomosynthesis - Andrew Smith, Ph.D., Hologic, Inc., Bedford, Mass., USA
      
• Nine 75-minute breast tomosynthesis education sessions from March 7th thru the 10th. Each session includes hands-on experience reading breast tomosynthesis images in combination with conventional and synthesized 2D images.
       
• Twelve tomosynthesis-guided breast biopsy training workshops. Each workshop will include an overview of the first clinical experiences with vacuum-assisted breast biopsies guided by tomosynthesis prior to a demonstration of a phantom procedure. There will be time at the end of each session for hands-on training.

For additional information and registration information, please email [email protected].  

Breast Tomosynthesis Innovations 

Hologic's widely-acclaimed Selenia Dimensions breast tomosynthesis system will be featured prominently at the Congress, along with the most recent innovation for the 3D technology platform – a tomosynthesis biopsy option for the Affirm breast biopsy guidance system. Hologic's tomosynthesis systems have been installed in over 50 countries since receiving CE marking in 2008 and in 48 states in the U.S. since receiving Food and Drug Administration approval in 2011. 

Hologic's new tomosynthesis biopsy option for the Affirm system is a revolutionary advance in 3D imaging, designed to allow radiologists to use the Company's tomosynthesis technology to accurately locate regions of interest for biopsy, even areas visible only on tomosynthesis images. Fewer exposures are required to complete a biopsy using tomosynthesis, compared to a stereotactic biopsy, resulting in an overall reduction in radiation dose.

Synthesized 2D images created using the latest version of Hologic's C-View software will also be on display at the Congress. C-View images are designed to provide workflow efficiencies and offer a lower dose alternative for patients. 

Other New Innovations

In addition to innovations in tomosynthesis and an extensive suite of established, world-class imaging solutions, Hologic will display two new products at ECR this year:

Shown for the first time in Europe is Hologic's Selenia Dimensions Avia Package. The Dimensions Avia Package offers an efficient option for customers seeking a 2D screening only or 2D screening and diagnostic solution. Customers can start with the cost-effective Avia Package today and upgrade in the future to applications including interventional and tomosynthesis capabilities.

Hologic's Fluoroscan InSight-FD Mini C-arm with flat panel detector technology, shown as work-in-progress last year, is designed specifically for orthopedic and extremity surgeons and offers a thin profile and improved workspace access with enhanced ease of positioning.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products. The Company operates four core business units focused on diagnostics, breast health, GYN surgical, and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.

Hologic, Affirm, C-View, Dimensions, Fluoroscan and Selenia are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Contacts:

SOURCE Hologic, Inc.